Skip to main content

COVID-19 is an emerging, rapidly evolving situation.

What people with cancer should know: https://www.cancer.gov/coronavirus

Guidance for cancer researchers: https://www.cancer.gov/coronavirus-researchers

Get the latest public health information from CDC: https://www.coronavirus.gov

Get the latest research information from NIH: https://www.nih.gov/coronavirus

Grant Details

Grant Number: 5R21CA229037-03 Interpret this number
Primary Investigator: Gulley, Margaret
Organization: Univ Of North Carolina Chapel Hill
Project Title: Endogenus Toolkit: a Biometric Method for Absolute Quantification of Tumor Markers By Massive Parallel Sequencing
Fiscal Year: 2020


Abstract

While massive parallel sequencing technology is quite mature, a problematic aspect is that plasma tumor markers are measured relative to total DNA, and total DNA levels vary with biologic factors like inflammation and with pre-analytic interferences such as leukocyte lysis during blood collection and handling ex vivo. This research aims to develop a novel strategy to quantify tumor markers in ‘copies per mL of plasma’, thus harmonizing the massive parallel sequencing assay with gold standard values generated by quantitative PCR. First, we will spike plasma with synthetic DNAs (called “EndoGenus Spikes”) which are then targeted for enrichment during library preparation and are quantified using informatic scripts after massive parallel sequencing. By normalizing levels of each tumor marker to the fractional recovery of spiked DNAs, numerical values are reportable in units of “copies per mL of plasma”, which we will show reflect clonal abundance. This new capability for absolute quantification of clonal abundance is likely to benefit basic scientists studying tumor heterogeneity and clonal evolution, and is likely to benefit patients and healthcare providers who seek more informative ways to monitor tumor burden, to evaluate the impact of medical interventions, and to find emerging drug resistance clones so that alternate therapy may be considered in a timely fashion. At the conclusion of this study, we will have developed and validated the ‘EndoGenus Toolkit’, comprised of synthetic DNAs, reagents to enrich for them during library preparation, and bioinformatic scripts to convert tumor marker levels from fractions to absolute concentrations. We will show that applying the ‘Toolkit’ to mock plasma specimens yields sensitive, specific, linear and reproducible sequencing results for multiple tumor markers. In blood from active cancer subjects, we will show that the ‘Toolkit’ helps overcome pre-analytic problems associated with blood storage. These tools should facilitate future clinical trials aimed at setting numeric thresholds for changing patient management.



Publications

Use of Spiked Normalizers to More Precisely Quantify Tumor Markers and Viral Genomes by Massive Parallel Sequencing of Plasma DNA.
Authors: Gulley M.L. , Elmore S. , Gupta G.P. , Kumar S. , Egleston M. , Hoskins I.J. , Garnett A. .
Source: The Journal of molecular diagnostics : JMD, 2020 04; 22(4), p. 437-446.
EPub date: 2020-02-07.
PMID: 32036092
Related Citations

Multilaboratory Assessment of a New Reference Material for Quality Assurance of Cell-Free Tumor DNA Measurements.
Authors: He H.J. , Stein E.V. , Konigshofer Y. , Forbes T. , Tomson F.L. , Garlick R. , Yamada E. , Godfrey T. , Abe T. , Tamura K. , et al. .
Source: The Journal of molecular diagnostics : JMD, 2019 07; 21(4), p. 658-676.
EPub date: 2019-05-02.
PMID: 31055023
Related Citations




Back to Top